TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01505114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300-mg tablet, once daily, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300-mg tablet, once daily, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300-mg tablet, once daily, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200-mg capsule, once daily, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200-mg capsule, once daily, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet, once daily, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet, once daily, from Week 0 through Week 48

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maraviroc placebo
Description: Once daily from Week 0 through Week 48

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emtricitabine placebo
Description: Once daily from Week 0 through Week 48

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emtricitabine placebo
Description: Once daily from Week 0 through Week 48

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate placebo
Description: Once daily from Week 0 through Week 48

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate placebo
Description: Once daily from Week 0 through Week 48
Study: NCT04967911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization exercises
Description: PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
Study: NCT03837197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver-Hypothermic oxygenated
Description: Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
Study: NCT03310879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
Study: NCT02770560

Intervention type: DEVICE
Intervention: Urokinase locking solution
Description: On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
Study: NCT04144244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MicroFluidic Sperm Sorting Chips
Description: sperm selection of IUI treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradient-Density Centrifugation
Description: sperm selection of IUI treatment
Study: NCT01850771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx PL-Disc
Description: Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Epidural
Description: Injection into the epidural space under image guidance of 3 mg of betamethasone.
Study: NCT01666574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test cereal 1, Oat-based
Description: The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test cereal 1, Oat-based
Description: The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Cereal 2, Oat based
Description: The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
Study: NCT00534560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets; 4 week dose titration with 16 weeks at target dose
Study: NCT01666574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Cereal 2, Oat based
Description: The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
Study: NCT02228460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ/SAR402671
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Study: NCT03090178

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic-Patient Report Outcome and wear of a wristband actigraph
Description: Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic-Patient Report Outcome and wear of a wristband actigraph
Description: Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
Study: NCT01243892

Intervention type: DEVICE
Intervention: NuSpin
Description: Device for administration of doses of somatropin.

Intervention type: DEVICE
Intervention: NuSpin
Description: Device for administration of doses of somatropin.

Intervention type: DRUG
Intervention: Somatropin
Description: Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.

Intervention type: DRUG
Intervention: Somatropin
Description: Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
Study: NCT05090059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb myofascial trigger points f-ESWT
Description: 3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb myofascial trigger points f-ESWT
Description: 3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
Study: NCT04302298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A machine which immerses the participant in a simulated environment where they can perform a procedure.
Study: NCT02936830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Sodium Fluoride Varnish
Description: 5% sodium fluoride varnish applied on the dentin by the dentist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% Nanohydroxyapetite paste
Description: 15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerol
Description: Glycerol with water in a 1: 1 ratio
Study: NCT02591069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation device
Description: All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
Study: NCT02627144

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.

Intervention type: DRUG
Intervention: Interferon alpha-2a
Description: Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
Study: NCT02825056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Morphine
Description: Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
Study: NCT00597181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with mitomycin c
Description: mitomycin c 0.2 mg/cc for 2 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ex-Press mini shunt with mitomycin c
Description: mitomycin c 0.2 mg/cc for 2 minutes
Study: NCT03548259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma
Description: Platelet-poor plasma injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-poor plasma
Description: Platelet-poor plasma injection
Study: NCT04476069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBUPROFEN
Description: given to children 30 minutes before extraction / orally for one time only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IBUPROFEN
Description: given to children 30 minutes before extraction / orally for one time only
Study: NCT04357132

Intervention type: OTHER
Group type: OTHER
Intervention: VR-Biofeedback
Description: Participants will be instructed to use the Mindful Aurora Application

Intervention type: OTHER
Group type: OTHER
Intervention: VR-Distraction
Description: Participants will be instructed to use one of four applications
Study: NCT04547569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibrotactile Discrimination
Description: Vibrotactile Discrimination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI measurement of brain activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI measurement of brain activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI measurement of brain activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech production
Description: Speech production task
Study: NCT00654420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
Study: NCT00287885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
Study: NCT02957305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 400mcg Tab
Description: 400µg of misoprostol (2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: 200µg of misoprostol (1 tablet)
Study: NCT03801291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal repair
Description: Vaginal incision through which plication of the rectovaginal septum is done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal repair
Description: Perineal incision through which plication of the rectovaginal septum is done
Study: NCT03911804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bolus group and infusion group for epidural block
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bolus group and infusion group for epidural block
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
Study: NCT02008201

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Study: NCT01111097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
Study: NCT02137174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home and school visits
Description: Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
Study: NCT04007718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation bias training
Description: Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interpretation bias training
Description: Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
Study: NCT02581514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled exams and diagnosis
Description: Scheduled exams and diagnosis circuit as imposed by the algorithm
Study: NCT03059602

Intervention type: OTHER
Intervention: No specific treatment based intervention-health measurement instrument
Description: Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
Study: NCT03632304

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with minimal sedation
Description: The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
Study: NCT03059602

Intervention type: OTHER
Intervention: No specific treatment based intervention-health measurement instrument
Description: Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)

Intervention type: OTHER
Intervention: No specific treatment based intervention-health measurement instrument
Description: Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
Study: NCT02444520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated GP Care
Description: The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed.
Study: NCT00427843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home exercise program for the hip abductor muscles
Description: All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns.
Study: NCT03012438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRF imaging in thyroid surgery
Description: a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
Study: NCT02994212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monthly distribution of RUTF
Description: 115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.